ES3064032T3 - Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies - Google Patents

Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies

Info

Publication number
ES3064032T3
ES3064032T3 ES18813969T ES18813969T ES3064032T3 ES 3064032 T3 ES3064032 T3 ES 3064032T3 ES 18813969 T ES18813969 T ES 18813969T ES 18813969 T ES18813969 T ES 18813969T ES 3064032 T3 ES3064032 T3 ES 3064032T3
Authority
ES
Spain
Prior art keywords
brimonidine
ketotifen
allergies
treatment
ophthalmological compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18813969T
Other languages
English (en)
Inventor
Gerald Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eye Therapies LLC
Original Assignee
Eye Therapies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eye Therapies LLC filed Critical Eye Therapies LLC
Application granted granted Critical
Publication of ES3064032T3 publication Critical patent/ES3064032T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18813969T 2017-06-08 2018-06-07 Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies Active ES3064032T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516931P 2017-06-08 2017-06-08
US201862621082P 2018-01-24 2018-01-24
PCT/US2018/036440 WO2018226942A1 (en) 2017-06-08 2018-06-07 Low-dose brimonidine combinations and uses thereof

Publications (1)

Publication Number Publication Date
ES3064032T3 true ES3064032T3 (en) 2026-04-22

Family

ID=64562826

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18813969T Active ES3064032T3 (en) 2017-06-08 2018-06-07 Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies

Country Status (20)

Country Link
US (2) US20180353504A1 (es)
EP (2) EP3634415B1 (es)
JP (3) JP2020523312A (es)
KR (2) KR20240090655A (es)
CN (2) CN117122600A (es)
AU (2) AU2018279074B2 (es)
CA (1) CA3066398A1 (es)
CL (3) CL2019003572A1 (es)
DK (1) DK3634415T3 (es)
ES (1) ES3064032T3 (es)
FI (1) FI3634415T3 (es)
LT (1) LT3634415T (es)
MX (3) MX2019014748A (es)
MY (1) MY205909A (es)
NZ (1) NZ760151A (es)
PL (1) PL3634415T3 (es)
PT (1) PT3634415T (es)
RS (1) RS67824B1 (es)
SG (1) SG11201911750RA (es)
WO (2) WO2018226942A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3817751T3 (pl) 2018-07-03 2025-09-08 Fennec Pharmaceuticals, Inc. Postacie użytkowe bezwodnego tiosiarczanu sodu
UA129938C2 (uk) * 2020-04-29 2025-09-17 Сентісс Фарма Прайвет Лімітед Офтальмологічні композиції, що містять комбінацію бринзоламіду та бримонідину
US20230201117A1 (en) * 2020-05-27 2023-06-29 Lupin Limited Ophthalmic nanoemulsion compositions
JP2022075651A (ja) * 2020-11-06 2022-05-18 千寿製薬株式会社 眼科用液体製剤
KR102444571B1 (ko) * 2020-11-18 2022-09-19 주식회사태준제약 세티리진 및 토코페솔란을 포함하는 안과용 조성물
CN114796219B (zh) * 2022-05-18 2024-08-20 沈阳药科大学 一种用于治疗青光眼的复方药物组合物及其用途
WO2024028815A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising an anti-allergen and a redness reduction agent
CA3264067A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS-REDUCING AGENT
CN120284871B (zh) * 2025-05-09 2026-03-10 南京帝昌医药科技有限公司 用于鼻腔的含奥洛他定与溴莫尼定的复方制剂组合物及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
PT1534313E (pt) * 2002-07-30 2013-01-25 Omeros Corp Soluções e método de irrigação oftalmológica
CN100463668C (zh) * 2005-05-09 2009-02-25 凌沛学 可逆性热凝胶化水性药物组合物
EP2471507B1 (en) * 2006-09-29 2017-03-01 Johnson & Johnson Vision Care, Inc. Ophthalmic devices used in the treatment of ocular allergies
ITMI20070890A1 (it) * 2007-05-04 2008-11-05 Sifi Spa Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
WO2009084021A2 (en) * 2007-10-16 2009-07-09 Sun Pharma Advanced Research Company Limited Novel ophthalmic compositions
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
US12246013B2 (en) * 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
AU2010226249A1 (en) * 2009-03-17 2011-10-13 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
CA2755679C (en) * 2009-03-17 2017-09-12 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
MX2011013060A (es) * 2009-06-05 2012-02-28 Aciex Therapeutics Inc Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
US8445526B2 (en) * 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
US20130203813A1 (en) * 2011-05-04 2013-08-08 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
JP2014520895A (ja) * 2011-07-20 2014-08-25 アラーガン インコーポレイテッド ビマトプロストおよびブリモニジンの固定用量の組み合わせ
US20140194527A1 (en) * 2012-02-29 2014-07-10 Rohto Usa, Inc. Geranylgeranylacetone formulations and retinal delivery thereof
EP2841104A1 (en) * 2012-04-24 2015-03-04 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
US9833441B2 (en) * 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) * 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
WO2015138786A1 (en) * 2014-03-12 2015-09-17 The Trustees Of Columbia University In The City Of New York Cosmetic preservatives as therapeutic corneoscleral tissue cross-linking agents
US20180250313A1 (en) * 2015-09-08 2018-09-06 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
US9694003B2 (en) * 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
US20200197398A1 (en) * 2017-06-08 2020-06-25 Eye Therapies, Llc Netarsudil and low-dose brimonidine combination and uses thereof

Also Published As

Publication number Publication date
KR20240090655A (ko) 2024-06-21
EP4691568A2 (en) 2026-02-11
NZ760151A (en) 2025-11-28
MY205909A (en) 2024-11-20
EP3634415B1 (en) 2026-02-11
CL2022002564A1 (es) 2023-05-26
MX2022008479A (es) 2022-08-02
AU2018279074B2 (en) 2023-12-14
CL2019003572A1 (es) 2020-04-24
BR112019025987A2 (pt) 2020-06-30
MX2022008478A (es) 2022-08-02
SG11201911750RA (en) 2020-01-30
CN110996954A (zh) 2020-04-10
EP3634415A4 (en) 2021-03-17
JP2024164101A (ja) 2024-11-26
CN117122600A (zh) 2023-11-28
KR20200018580A (ko) 2020-02-19
EP3634415A1 (en) 2020-04-15
PT3634415T (pt) 2026-03-05
AU2023282222A1 (en) 2024-01-04
AU2018279074A1 (en) 2020-01-16
CL2022002566A1 (es) 2023-05-26
LT3634415T (lt) 2026-04-10
WO2019236148A1 (en) 2019-12-12
AU2023282222B2 (en) 2025-06-26
RU2019144001A3 (es) 2022-03-05
FI3634415T3 (fi) 2026-03-24
JP2023055823A (ja) 2023-04-18
CA3066398A1 (en) 2018-12-13
RS67824B1 (sr) 2026-03-31
US20180353504A1 (en) 2018-12-13
RU2019144001A (ru) 2021-07-09
MX2019014748A (es) 2020-08-03
DK3634415T3 (da) 2026-03-09
JP2020523312A (ja) 2020-08-06
PL3634415T3 (pl) 2026-04-07
US20220233524A1 (en) 2022-07-28
WO2018226942A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
ES3064032T3 (en) Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies
EP3680856C0 (en) ASSESSMENT OF DENTAL TREATMENTS AND PROCEDURES BASED ON PHOTOGRAPHS
IL252943A0 (en) Sunitinib formulations and methods of using them for the treatment of eye diseases
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
PL3381451T3 (pl) Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
SMT202500469T1 (it) Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla
PL3532459T3 (pl) Inhibitory lsd1 i ich zastosowania medyczne
PT4101454T (pt) Composições para utilização no tratamento da hipertensão
IL251351B (en) Preparations for use in the treatment and prevention of surgical infections
IL257296B (en) Methods of sedation and intravenous vehicle for use during critical care
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
LT3373922T (lt) Kompozicijos ir būdai skirti naudoti homocistinurijos gydyme
IL246587A0 (en) Preparations for use in the treatment of allergic conditions
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
SG11201809811VA (en) Compositions and methods for treatment of inflammation or infection of the eye
EP3664773A4 (en) Hair treatment compositions and methods
PL3478260T3 (pl) Kompozycja do pielęgnacji skóry i jej zastosowanie
SMT202100070T1 (it) Complesso e composizioni per il trattamento di affezioni oculari e cutanee
IL251407A0 (en) A multivalent compound for the treatment and prevention of brain damage
PL2862576T3 (pl) Drobnoustroje i zawierające je kompozycje do stosowania do leczenia lub profilaktyki zapalenia sutka
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
ZA201403582B (en) Composition for use in treatment of anemia and low blood pressure
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases